NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

Inclusion Criteria: * Ability to provide signed, written informed consent * Histologically or cytologically confirmed non-metastatic adenocarcinoma of the breast (stage I-II) * Candidate for curative-intent treatment * ER+ and/or PR+ and HER2-positive (Fluorescence In Situ Hybridization-positive or 3+ by Immunohistochemistry staining) * Life expectancy greater than 5 years * Left Ventricular Ejection Fraction \> 50% at baseline (within 30 days of day 0) * Eastern Cooperative Oncology Group performance status ≤2 * Absolute Neutrophil Count \>1000/µL * Platelets ≥50,000/µL * Hemoglobin \>8.0 g/dL, * Creatinine ≤3.0 x upper limit of normal (ULN) * Bilirubin ≤3.0 x ULN * Aspartate aminotransferase or Alanine aminotransferase \<5.0 x ULN * Negative serum pregnancy test for women \<12 months after the onset of menopause unless surgically sterilized * Agreement by women of childbearing potential and male participants with partners of childbearing potential to use a "highly effective", non-hormonal form of contraception or two "effective" forms of non-hormonal contraception by the patient and/or partner. Exclusion Criteria: * Active infection * Presence of known metastases (stage IV disease) * Pregnant or lactating women * Prior chemotherapy or radiation therapy for the primary breast cancer * Concomitant malignancies or previous malignancies within the last 5 years except adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. * History of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias * Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary or metabolic disease including diabetes, wound healing disorders, ulcers or bone fractures) * Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipated need for major surgery during the course of study treatment * Current known infection with Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) or Hepatitis C Virus (HCV) * Receipt of intravenous antibiotics for infection within 14 days prior to receiving study treatment * Current chronic daily treatment with corticosteroids (dose \>10 mg/day methylprednisolone equivalent) except inhaled steroids * Known hypersensitivity to any of the study drugs * Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol